#3-86E. A New Frontier in Refractory Behçet's Syndrome: The Upadacitinib Trial (ART, 2026)

Are you struggling to find effective treatment options for patients with refractory Behçet’s syndrome who have already failed standard biologic therapies? In this episode, we explore a recent multi-centre, single-arm trial evaluating the efficacy and safety of upadacitinib, a selective JAK1 inhibitor, in 27 patients with refractory Behçet’s syndrome. Administered at 15 mg daily, upadacitinib demonstrated a remarkable overall response rate of 85.2% at 24 weeks, alongside significant reductions in disease activity scores, inflammatory markers, and daily glucocorticoid requirements. The most critical clinical takeaway is that upadacitinib offers a highly promising, steroid-sparing therapeutic alternative, showing robust efficacy even as a subsequent line of targeted therapy for severe cases. However, when critically appraising this evidence, physicians must carefully consider the study's primary limitations: its small sample size and the absence of a randomized control group, meaning these encouraging findings require further validation8. For practicing clinicians, this study provides vital insight into a potential "next-step" strategy, equipping you with a novel targeted approach to manage challenging, treatment-resistant Behçet’s syndrome in your daily practice.

Citation: Jiachen Li, Tian Liu, Zhanguo Li, et al. Upadacitinib for refractory Behcet’s syndrome: a multi-centre, single-arm trial. Arthritis Res Ther. 2026 Mar 3. doi: 10.1186/s13075-026-03778-x. Online ahead of print.

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.